Top

Published in:

01-01-2014 | Preclinical study

Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers

Authors: Surojeet Sengupta, Michael C. Biarnes, V. Craig Jordan

Published in: Breast Cancer Research and Treatment | Issue 1/2014

Abstract

Endocrine therapy resistance in estrogen receptor alpha positive (ERα+) breast cancers remains a major obstacle for maintaining efficacy of targeted therapies. We investigated the significance and the mechanisms involved in cMYC over-expression in a MCF7 derived panel of ERα+ breast cancer cells which can proliferate in the absence of estrogen with different sensitivities to anti-hormone therapies. We show that all the resistant cell lines tested over-express cMYC as compared to parental MCF7 cells and its inhibition lead to the differential blocking of estrogen-independent proliferation in resistant cells. Further investigation of the resistant cell line, MCF7:5C, suggested transcriptional de-regulation of cMYC gene was responsible for its over-expression. Chromatin immuno-precipitation assay revealed markedly higher recruitment of phosphorylated serine-2 carboxy-terminal domain (CTD) of RNA polymerase-II at the proximal promoter of cMYC gene, which is responsible for transcriptional elongation of the cMYC RNA. The level of CDK9, a factor responsible for the phosphorylation of serine-2 of RNA polymerase II CTD, was found to be elevated in all the resistant cell lines. Pharmacological inhibition of CDK9 not only reduced the transcripts and the protein levels of cMYC in MCF7:5C cells but also selectively inhibited the estrogen-independent growth of all the resistant cell lines. This study describes the up-stream molecular events involved in the transcriptional over-expression of cMYC gene in breast cancer cells proliferating estrogen-independently and identifies CDK9 as a potential novel drug target for therapeutic intervention in endocrine-resistant breast cancers.

Available only for authorised users

Sengupta S, Jordan VC (2008) Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 630:206–219PubMedCrossRef

Obiorah I, Jordan VC (2011) Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas 70(4):315–321. doi:10.1016/j.maturitas.2011.09.006 PubMedCentralPubMedCrossRef

Jordan VC, O’Malley BW (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25(36):5815–5824. doi:10.1200/JCO.2007.11.3886 PubMedCrossRef

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664–1670. doi:10.1200/JCO.2007.13.5822 PubMedCrossRef

Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22):3758–3767PubMed

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. doi:10.1056/NEJMoa1109653 PubMedCrossRef

McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, Murphy NC, Millar EK, Crea P, Kench JG, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ, Henshall SM, Musgrove EA, Sutherland RL (2006) c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol 102(1–5):147–155. doi:10.1016/j.jsbmb.2006.09.028 PubMedCrossRef

Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353–360. doi:10.1038/nature11143 PubMedCentralPubMed

Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL (2011) A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 17(7):2024–2034. doi:10.1158/1078-0432.CCR-10-2567 PubMedCentralPubMedCrossRef

10.

Venditti M, Iwasiow B, Orr FW, Shiu RP (2002) c-Myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 99(1):35–42. doi:10.1002/ijc.10269 PubMedCrossRef

11.

Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S (2010) MYC regulation of a “poor-prognosis” metastatic cancer cell state. Proc Natl Acad Sci U S A 107(8):3698–3703. doi:10.1073/pnas.0914203107 PubMedCentralPubMedCrossRef

12.

Heselmeyer-Haddad K, Berroa Garcia LY, Bradley A, Ortiz-Melendez C, Lee WJ, Christensen R, Prindiville SA, Calzone KA, Soballe PW, Hu Y, Chowdhury SA, Schwartz R, Schaffer AA, Ried T (2012) Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of myc during progression. Am J Pathol 181(5):1807–1822. doi:10.1016/j.ajpath.2012.07.012 PubMedCrossRef

13.

Deming SL, Nass SJ, Dickson RB, Trock BJ (2000) C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83(12):1688–1695. doi:10.1054/bjoc.2000.1522 PubMedCentralPubMedCrossRef

14.

Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10):740–749. doi:10.1038/nrc906nrc906 PubMedCrossRef

15.

Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI (2008) Modelling Myc inhibition as a cancer therapy. Nature 455(7213):679–683. doi:10.1038/nature07260 PubMedCrossRef

16.

Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, Bishop JM (2001) c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 414(6865):768–773. doi:10.1038/414768a PubMedCrossRef

17.

Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, Frazier J, Chau BN, Loboda A, Linsley PS, Cleary MA, Park JR, Grandori C (2012) Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 109(24):9545–9550. doi:10.1073/pnas.1121119109 PubMedCrossRef

18.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904–917. doi:10.1016/j.cell.2011.08.017 PubMedCentralPubMedCrossRef

19.

Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC (1992) An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90(1):77–86PubMedCrossRef

20.

Pink JJ, Jiang SY, Fritsch M, Jordan VC (1995) An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kDa estrogen receptor-related protein. Cancer Res 55(12):2583–2590PubMed

21.

Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R (1993) Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53(2):283–290PubMed

22.

Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R (1993) MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53(14):3229–3232PubMed

23.

Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R (1997) MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 57(16):3486–3493PubMed

24.

Sweeney EE, McDaniel RE, Maximov PY, Fan P, Jordan VC (2012) Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Horm Mol Biol Clin Investig 9(2):143–163. doi:10.1515/hmbci-2011-0004 PubMedCentralPubMed

25.

Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VC (2011) Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci USA 108(47):18879–18886. doi:10.1073/pnas.1115188108 PubMedCrossRef

26.

Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC (2005) Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97(23):1746–1759. doi:10.1093/jnci/dji400 PubMedCrossRef

27.

Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302(7):774–780. doi:10.1001/jama.2009 PubMedCentralPubMedCrossRef

28.

Sengupta S, Obiorah I, Maximov P, Curpan R, Jordan VC (2013) Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol 169(1):167–178. doi:10.1111/bph.12122 PubMedCrossRef

29.

Yin X, Giap C, Lazo JS, Prochownik EV (2003) Low molecular weight inhibitors of Myc–Max interaction and function. Oncogene 22(40):6151–6159. doi:10.1038/sj.onc.1206641 PubMedCrossRef

30.

Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ (2008) Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol 15(11):1149–1155. doi:10.1016/j.chembiol.2008.09.011 PubMedCrossRef

31.

Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725–731. doi:10.1007/s10549-009-0674-9 PubMedCrossRef

32.

Saunders A, Core LJ, Lis JT (2006) Breaking barriers to transcription elongation. Nat Rev Mol Cell Biol 7(8):557–567. doi:10.1038/nrm1981 PubMedCrossRef

33.

Shim EY, Walker AK, Shi Y, Blackwell TK (2002) CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo. Genes Dev 16(16):2135–2146. doi:10.1101/gad.999002 PubMedCrossRef

34.

Larochelle S, Amat R, Glover-Cutter K, Sanso M, Zhang C, Allen JJ, Shokat KM, Bentley DL, Fisher RP (2012) Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol 19(11):1108–1115. doi:10.1038/nsmb.2399 PubMedCentralPubMedCrossRef

35.

Sims RJ 3rd, Belotserkovskaya R, Reinberg D (2004) Elongation by RNA polymerase II: the short and long of it. Genes Dev 18(20):2437–2468. doi:10.1101/gad.1235904 PubMedCrossRef

36.

Krystof V, Cankar P, Frysova I, Slouka J, Kontopidis G, Dzubak P, Hajduch M, Srovnal J, de Azevedo WF, Jr Orsag M, Orsag M Jr, Paprskarova M, Rolcik J, Latr A, Fischer PM, Strnad M (2006) 4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 49(22):6500–6509. doi:10.1021/jm0605740 PubMedCrossRef

37.

Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247. doi:10.1146/annurev-med-070909-182917 PubMedCentralPubMedCrossRef

38.

Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ (1998) Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139(10):4164–4174PubMedCrossRef

39.

Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81(3):323–330PubMedCrossRef

40.

Bentley DL, Groudine M (1986) A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 321(6071):702–706. doi:10.1038/321702a0 PubMedCrossRef

41.

Krumm A, Meulia T, Brunvand M, Groudine M (1992) The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region. Genes Dev 6(11):2201–2213PubMedCrossRef

42.

Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH (2011) Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 25(9):1527–1538. doi:10.1210/me.2011-1037 PubMedCrossRef

43.

Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schutte J, Gardiner-Garden M, Ormandy CJ, McArthur G, Butt AJ, Sutherland RL (2008) Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS ONE 3(8):e2987. doi:10.1371/journal.pone.0002987 PubMedCentralPubMedCrossRef

44.

Kininis M, Isaacs GD, Core LJ, Hah N, Kraus WL (2009) Postrecruitment regulation of RNA polymerase II directs rapid signaling responses at the promoters of estrogen target genes. Mol Cell Biol 29(5):1123–1133. doi:10.1128/MCB.00841-08 PubMedCentralPubMedCrossRef

45.

Nechaev S, Adelman K (2011) Pol II waiting in the starting gates: regulating the transition from transcription initiation into productive elongation. Biochim Biophys Acta 1809:34–45. doi:10.1016/j.bbagrm.2010.11.001 PubMedCentralPubMedCrossRef

46.

Buratowski S (2009) Progression through the RNA polymerase II CTD cycle. Mol Cell 36(4):541–546. doi:10.1016/j.molcel.2009.10.019 PubMedCentralPubMedCrossRef

47.

Peterlin BM, Price DH (2006) Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23(3):297–305. doi:10.1016/j.molcel.2006.06.014 PubMedCrossRef

48.

Baumli S, Hole AJ, Noble ME, Endicott JA (2012) The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508. ACS Chem Biol 7(5):811–816. doi:10.1021/cb2004516 PubMedCentralPubMedCrossRef

49.

Zhang W, Prakash C, Sum C, Gong Y, Li Y, Kwok JJ, Thiessen N, Pettersson S, Jones SJ, Knapp S, Yang H, Chin KC (2012) Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem 287(51):43137–43155. doi:10.1074/jbc.M112.413047 PubMedCrossRef

50.

Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 19(4):523–534. doi:10.1016/j.molcel.2005.06.027 PubMedCrossRef

51.

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478(7370):524–528. doi:10.1038/nature10334 PubMedCentralPubMedCrossRef

Title: Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers
Authors: Surojeet Sengupta
Michael C. Biarnes
V. Craig Jordan
Publication date: 01-01-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2789-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis

Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers

Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer

DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin

Adeno-associated virus-mediated expression of recombinant CBD–HepII polypeptide of human fibronectin inhibits metastasis of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer